Travere Therapeutics (TVTX) reported $164.86 million in revenue for the quarter ended September 2025, representing a year-over-year increase of 162.1%. EPS of $0.28 for the same period compares to -$0.70 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $103.39 million, representing a surprise of +59.45%. The company delivered an EPS surprise of +190.32%, with the consensus EPS estimate being -$0.31.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Travere performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue- Tiopronin products / Thiola: $22.25 million versus $22.64 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a -12.3% change.
- Total net product sales: $113.15 million compared to the $99.66 million average estimate based on six analysts. The reported number represents a change of +85.5% year over year.
- Revenue- FILSPARI: $90.9 million versus $77.02 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +155.2% change.
- Revenue- License and collaboration revenue: $51.71 million compared to the $4.23 million average estimate based on five analysts. The reported number represents a change of +2625.8% year over year.
View all Key Company Metrics for Travere here>>>
Shares of Travere have returned +20.9% over the past month versus the Zacks S&P 500 composite's +3.6% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Travere Therapeutics, Inc. (TVTX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
